I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Drilon, A.
290
results:
OpenAccess-fulltext X
Search for persons
X
Languages
english (245)
swedish (8)
Sorted by: Relevance
Sorted by: Year
?
1
Selpercatinib in Patients With RET Fusion-Positive Non-Smal..:
Drilon, A
;
Subbiah, V
;
Gautschi, O
...
issn:0732-183X. , 2023
Link:
http://hdl.handle.net/11..
?
2
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion..:
Drilon, A
;
Chiu, C-H
;
Fan, Y
...
issn:2666-3643. , 2022
Link:
http://hdl.handle.net/11..
?
3
HGG-11. Clinical characteristics and clinical evolution of ..:
Lamoureux, A-A
;
Fisher, M
;
Lemelle, L
...
issn:1522-8517. , 2022
Link:
http://hdl.handle.net/11..
?
4
Efficacy and Safety of Larotrectinib in Patients With Tropo..:
Drilon, A
;
Tan, DSW
;
Lassen, UN
...
issn:2473-4284. , 2022
Link:
http://hdl.handle.net/11..
?
5
Updated Integrated Analysis of the Efficacy and Safety of E..:
Demetri, GD
;
De Braud, F
;
Drilon, A
...
issn:1078-0432. , 2022
Link:
http://hdl.handle.net/11..
?
6
Safety and preliminary clinical activity of NVL-520, a high..:
Drilon, A
;
Besse, B
;
Camidge, D. R
...
https://research.rug.nl/en/publications/b52614c4-19e2-4f15-95fc-78b8da2b50e2. , 2022
Link:
https://hdl.handle.net/1..
?
7
Correlation between treatment effects on response rate and ..:
Solomon, BJ
;
Loong, HH
;
Summers, Y
...
issn:2059-7029. , 2022
Link:
http://hdl.handle.net/11..
?
8
Correlation between treatment effects on response rate and ..:
Solomon, B.J
;
Loong, H.H
;
Summers, Y
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058889/. , 2022
Link:
http://www.ncbi.nlm.nih...
?
9
Efficacy and safety of larotrectinib in TRK fusion-positive..:
Doz, F
;
van Tilburg, CM
;
Geoerger, B
...
issn:1522-8517. , 2022
Link:
http://hdl.handle.net/11..
?
10
Characterization and Management of ERK Inhibitor Associated..:
Wu, J
;
Liu, D
;
Offin, M
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282166/. , 2021
Link:
http://www.ncbi.nlm.nih...
?
11
Patient-reported outcomes from STARTRK-2: a global phase II..:
Paz Ares, Luis Gonzaga
;
Barlesi, F
;
Siena, S
...
https://doi.org/10.1016/j.esmoop.2021.100113.. , 2021
Link:
https://hdl.handle.net/2..
?
12
Efficacy and safety of larotrectinib in TRK fusion-positive..:
Doz, F
;
van Tilburg, CM
;
Geoerger, B
...
Neuro-Oncology. , 2021
Link:
https://repository.icr.a..
?
13
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3..:
Hui Gan
;
M Millward
;
M Jalving
...
doi:10.26181/61690d90917ee. , 2021
Link:
https://doi.org/10.26181..
?
14
Molecular Characteristics of Repotrectinib That Enable Pote..:
Murray, BW
;
Rogers, E
;
Zhai, D
...
issn:1535-7163. , 2021
Link:
http://hdl.handle.net/11..
?
15
Patient-reported outcomes from STARTRK-2: a global phase II..:
Paz-Ares, L
;
Barlesi, F
;
Siena, S
...
info:eu-repo/semantics/altIdentifier/pmid/33930659. , 2021
Link:
http://hdl.handle.net/24..
1-15
